Proteolytic and polymerase activity of thrombin

1960 ◽  
Vol 198 (1) ◽  
pp. 173-179 ◽  
Author(s):  
Ricardo H. Landaburu ◽  
Walter H. Seegers

In addition to splitting peptides from fibrinogen, thrombin is necessary for the polymerization of fibrin monomer. Thrombin also uses fibrin as a substrate and eventually the clot may lyse. On the basis of these views, previous equations used to outline the events when thrombin and fibrinogen are mixed can be revised as follows: Proteolysis: F + T ⇆ f + P + T (1) Polymerization: Nf + T ⇆ NfT (2) (fibrin clot) Proteolysis: NfT → Inf + T + P2 (3) F is fibrinogen, T is thrombin, f is fibrin monomer, P is peptides and carbohydrates, N is any number, Inf is inactive fibrin monomer, and P2 is peptides or any reaction products. As the thrombin concentration increases the polymerization time becomes shorter. TAMe retards the polymerization time. For a given thrombin concentration the clotting time of fibrinogen may be inversely proportional to the concentration of fibrinogen. Most of the clotting time is accounted for as polymerization time, but the amount of thrombin required for the latter is relatively small. In 3 m urea solution thrombin may irreversibly lose its activity. When protected by a substrate such as TAMe, fibrinogen or fibrin, thrombin is active in urea solution. The activity then depends upon TAMe concentration under conditions when the enzyme behaves as if saturated with the substrate. To have this activity in urea solution the substrate must be in the urea before the thrombin is added. Esterase thrombin also uses fibrin as a substrate; it is, however, not a polymerase. It does not use fibrinogen as a substrate.

1940 ◽  
Vol 23 (3) ◽  
pp. 289-300 ◽  
Author(s):  
Theodore Winnick ◽  
Alva R. Davis ◽  
David M. Greenberg

1. The kinetics of milk clotting by asclepain, the protease of Asclepias speciosa, were investigated. At higher concentrations of enzyme, the clotting time was inversely proportional to the enzyme concentration. 2. The digestion of casein and hemoglobin in 6.6 M urea by asclepain follows the second order reaction rate. The rate was roughly second order for casein in water. 3. Evaluation of the nature of the enzyme-substrate intermediate indicates that one molecule of asclepain combines with one molecule of casein or hemoglobin in urea solution. 4. Inhibition by the reaction products was deduced from the fact that the digestion velocity of hemoglobin in urea solution varied with the asclepain concentration in agreement with the Schütz-Borissov rule.


1987 ◽  
Vol 57 (01) ◽  
pp. 073-076 ◽  
Author(s):  
Gerard Marx ◽  
Pierre Hopmeier ◽  
Dorit Gurfel

SummaryTurbidimetric studies indicate that Zn(II) accelerates fibrin gelation [decreases clotting time (CT)] and increases maximal fibrin clot turbidity. For any given level of fibrinogen (0.2-2.6 mg/ ml), the relative fibrin turbidity of thrombin-induced clots increases with Zn(II) in a concentration dependent manner. Zinc-associated turbidity increases are also observed in the presence of 2 mM Ca(II). With citrate, similar turbidity increases are observed, though at higher cation levels. Thus, turbidimetry indicates that the gel formed with Zn(II) is coarser, or has thicker fibre strands. SEM micrographs confirm that fibre thickness ranges from 260 Å to 2600 Å, when Zn(II) levels range from 0-50 uM. With citrate, TEM micrographs reveal amore than 20 x fold increase in fibre diameter (100 Å->2000 Å) with higher Zn(II) (<1 mM) levels. Based on a fibrin monomer cross-section of ~60 Å, the electron micrographs indicate that depending on the Zn(II) levels, fibrin strands are composed of between 2 to 40 monomeric fibrin molecules. Thus, at physiologically relevant levels, Zn(II) can drastically modulate fibrin ultrastructure.


1976 ◽  
Vol 36 (01) ◽  
pp. 037-048 ◽  
Author(s):  
Eric P. Brass ◽  
Walter B. Forman ◽  
Robert V. Edwards ◽  
Olgierd Lindan

SummaryThe process of fibrin formation using highly purified fibrinogen and thrombin was studied using laser fluctuation spectroscopy, a method that rapidly determines particle size in a solution. Two periods in fibrin clot formation were noted: an induction period during which no fibrin polymerization occurred and a period of rapid increase in particle size. Direct measurement of fibrin monomer polymerization and fibrinopeptide release showed no evidence of an induction period. These observations were best explained by a kinetic model for fibrin clot formation incorporating a reversible fibrinogen-fibrin monomer complex. In this model, the complex serves as a buffer system during the earliest phase of fibrin formation. This prevents the accumulation of free polymerizable fibrin monomer until an appreciable amount of fibrinogen has reacted with thrombin, at which point the fibrin monomer level rises rapidly and polymerization proceeds. Clinically, the complex may be a homeostatic mechanism preventing pathological clotting during periods of elevated fibrinogen.


1984 ◽  
Vol 4 (1) ◽  
pp. 188-194
Author(s):  
B S Ben-Tzvi ◽  
Y Koltin ◽  
M Mevarech ◽  
A Tamarkin

RNA polymerase activity is associated with the double-stranded RNA virions of Ustilago maydis. The reaction products of the polymerase activity are single-stranded RNA molecules. The RNA molecules synthesized are homologous to the three classes of double-stranded RNA molecules that typify the viral genome. The single-stranded RNA synthesized is released from the virions. The molecular weight of the single-stranded RNA transcripts is about half the size of the double-stranded RNA segments, and thus, it appears that in the in vitro reaction, full-length transcripts can be obtained.


1987 ◽  
Author(s):  
C Zamarrón

In the fibrinolytic process: (a) fibrin provides a surface on which the major reactions of fibrinolysis occurs: the conversion of plasminogen to plasmin, the cleavage of fibrin by plasmin and the inhibition of plasmin by α2-antiplasmin, (b) some fibrinogen derivatives (e.g. the cyanogen bromide digested fibrinogen fragment denominated FCB-2) can exert stimulatory properties on the plasminogen activation and (c) the initial cleavage of fibrin by plasmin increases the rate conversion of plasminogen to plasmin.The purpose of the present work has been to correlate these three aspects of the fibrinolytic process with the binding of native plasminogen (Glu-Pg) to fibrin (Fn) , fibrinogen (Fg) and Fn/Fg derivatives.The Glu-Pg-Fg interaction, if exists, it is not detectable in equilibrium conditions by analytical centrifu gation. By using a solid-phase fibrin clot system (purified system) the Glu-Pg-Fn interaction gives the following dissociation constants: Kd=3.5×10−6 M and 1.2×10−5 m (unwashed and washed clots respectively). Being two the number of plasminogen binding sites per fibrin fibrin monomer. By activation with streptokinase or urokinase the amount of Pg required for an effective lysis of the fibrin clots is lower when the Pg is endogenous (inside the clot) versus exogenous (outside the clot).The binding of the isolated fragments of the cyanogen bromide digested fibrinogen to Glu-Pg was studied by affinity chromatography on Glu-Pg-Sepharose. The only fragment bound to Glu-Pg and eluted with 10 mM ε-amino caproic acid (ε;-ACA) was the fragment denominated FCB-2 The soluble fibrin monomer after 20 min plasmin digestion also binds to immobilized Glu-Pg and it is eluted with ε-ACA.Therefore, the binding of native plasminogen to fibrin and to some fibrinogen/fibrin derivatives is a determinant factor in the three aspects of the fibrinolytic process mencioned above.


1984 ◽  
Vol 4 (1) ◽  
pp. 188-194 ◽  
Author(s):  
B S Ben-Tzvi ◽  
Y Koltin ◽  
M Mevarech ◽  
A Tamarkin

RNA polymerase activity is associated with the double-stranded RNA virions of Ustilago maydis. The reaction products of the polymerase activity are single-stranded RNA molecules. The RNA molecules synthesized are homologous to the three classes of double-stranded RNA molecules that typify the viral genome. The single-stranded RNA synthesized is released from the virions. The molecular weight of the single-stranded RNA transcripts is about half the size of the double-stranded RNA segments, and thus, it appears that in the in vitro reaction, full-length transcripts can be obtained.


1976 ◽  
Vol 9 (4) ◽  
pp. 379-386 ◽  
Author(s):  
M.W. Rampling ◽  
D.A. Lane ◽  
V.V. Kakkar

1967 ◽  
Vol 126 (5) ◽  
pp. 979-988 ◽  
Author(s):  
B. Lipiński ◽  
J. Hawiger ◽  
J. Jeljaszewicz

Clumping reaction, using standard suspension of Staph. aureus Newman D-2-C strain and various substrates, was quantitatively tested. It has been shown that clumping occurs in fibrin lysate containing soluble fibrin monomer complexes unclottable by thrombin. The reaction was positive with staphylococcal strains possessing clumping factor regardless of staphylocoagulase production. Clumping reaction is similar to paracoagulation reaction induced by protamine sulfate. The substrate for both reactions is stable at 56°C but is destroyed at 60°C. The kinetics of substrate formation for both reactions during fibrin clot lysis is also similar. Clumping reaction with a strain of Staph. epidermidis possessing no clumping factor was positive when these bacteria were coated with protamine sulfate. The effect of heparin, sodium citrate, urea, 2-mercaptoethanol, merthiolate, and mucin on both reactions was tested. The present findings explain the clumping reaction in serum and emphasize the role of blood clotting and fibrinolytic systems in this phenomenon.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1150-1150
Author(s):  
Anton Matafonov ◽  
Suryakala Sarilla ◽  
Mao-fu Sun ◽  
John P. Sheehan ◽  
Vladimir Serebrov ◽  
...  

Abstract Abstract 1150 During plasma coagulation the protease α-thrombin (αIIa) cleaves fibrinogen to form a fibrin clot. Conversion of prothrombin to αIIa is catalyzed by factor (f) Xa, and results in expression of two electropositive regions on αIIa designated anion binding exosites (ABE) I and II. ABE I is involved in fibrinogen binding. In the presence of fVa and phospholipid, fXa cleaves prothrombin preferentially after Arg320, generating the intermediate meizothrombin (MzIIa), which also expresses ABE I. MzIIa is rapidly converted to αIIa. αIIa can be converted to β-thrombin (βIIa) and γ-thrombin (γIIa), both of which are cleaved within ABE I, and have greatly reduced capacity to convert fibrinogen to fibrin. Physiologic functions for βIIa or γIIa are not established; however, both have been identified in clotting blood. αIIa up-regulates its own generation in plasma by converting fXI to the protease fXIa. Yun et al. (J Biol Chem 2003;278:48112) showed that amino acids in ABE I are required for optimal fXI activation in the presence of the polyanion dextran sulfate (DS). MzIIa also activates fXI, consistent with a role for ABE I in protease binding to fXI. Given the absence of ABE I in βIIa and γIIa, it seems reasonable to postulate these proteases would interact poorly with fXI. In a clotting assay in which thrombin is added to plasma anticoagulated with citrate (low calcium), βIIa (12.5 nM) and γIIa (50 nM) did not induce clot formation, consistent with their low capacity to cleave fibrinogen. However, when plasma was recalcified to allow thrombin to form from endogenous prothrombin, both βIIa and γIIa induced clot formation. Recalcified plasma in the absence of βIIa or γIIa did not clot (800 sec observation period), indicating fibrin formation was βIIa/γIIa-dependent. Addition of an antibody to fXI prolonged the clotting time with βIIa, and prevented clotting with γIIa, suggesting βIIa and γIIa were activating fXI. In addition, with γIIa, a fXIIa inhibitor modestly prolonged clotting time, indicating the plasma contact phase was activated. We studied fXI activation by thrombin using western blot. βIIa and γIIa activated fXI at approximately half the rate of αIIa, while MzIIa activated fXI ∼4 fold faster than αIIa. FXI activation by αIIa is greatly enhanced by DS. In the presence of DS, αIIa and βIIa activated fXI comparably, while results with γIIa were not informative because the protease does not interact well with DS. Importantly, fXI activation by αIIa was not affected by the ABE I blocking peptide hirugen, indicating ABE I is not required for fXI activation by thrombin. While βIIa and γIIa were less effective fXI activators than αIIa and MzIIa in solution, significantly different results were obtained in a plasma thrombin generation assay. Here coagulation is initiated in fXII deficient plasma with thrombin (10 nM), and subsequent thrombin generation from endogenous prothrombin is monitored. The system is fXI-dependent, as a fXI antibody blocks thrombin generation. Prior work with this system indicates fXI is probably converted to fXIa by the thrombin added to initiate the process. Initiation of coagulation with αIIa and MzIIa resulted in comparable thrombin generation (∼250 nM). βIIa and γIIa, as well as recombinant αIIa with mutations in amino acids in ABE I induced thrombin generation ∼2-fold greater than for αIIa and MzIIa. We hypothesized this was due to the inability of fibrinogen to compete with fXI for binding to thrombin species lacking ABE I. Consistent with this, hirugen peptide enhanced αIIa initiated thrombin generation ∼4-fold. Finally, we followed up on the observation that a fXIIa inhibitor prolonged time to γIIa-induced clot formation in recalcified plasma. In solution, γIIa, but not αIIa, βIIa, or MzIIa cleaves the contact factors fXII and PK. The cleaved proteases, in turn, are capable of cleaving chromogenic substrates, and have activity in a reciprocal fXII-PK activation assay. Our studies show that ABE I is not required for thrombin-mediated activation of fXI, that thrombin species not fully expressing ABE I may be better than αIIa and MzIIa as initiators of fXI-dependent thrombin generation in plasma, and that γIIa can activate the plasma contact proteases. Taken as a whole, the data indicate forms of thrombin other than αIIa may contribute directly to feedback activation of fXI, and may represent a previously unrecognized link between coagulation and the contact system. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4770-4770
Author(s):  
Jawed Fareed ◽  
Debra Hoppensteadt ◽  
Omer Iqbal ◽  
Schuharazad Abro ◽  
Martin Emanuele

Background Poloxamer 188 (P188; Mast Therapeutics, Inc.) is a surface-active, non-ionic block copolymer which binds to hydrophobic surfaces on damaged cells improving membrane hydration and lowering adhesion and viscosity.  It is known to improve microvascular function in various pathologic states.  Currently, this agent is under investigation in a phase 3 clinical trial for treatment of sickle cell disease patients experiencing acute vaso-occlusive crisis.  The effect of P188 on blood coagulation and platelet function has been evaluated in several clinical trials where no clinically significant effect has been observed.   In these trials, coagulation studies were based on standard clot based methods (e.g., PT and aPTT) and did not include viscoelastic measurements such as thromboelastography (TEG).   Given P188 alters viscosity, we compared the effect of this agent using various clotbased, chromogenic and viscoelastic measurements of blood coagulation. Materials and Methods Whole blood activated clotting time studies were carried out in groups of healthy individuals (n=10) at a concentration range of 1.872-15.0mg/mL. TEG analysis on native and citratedwhole blood was carried out on TEG 5000 (Haemoscope Corp, Niles, IL) at concentrations of 0-0.45 mg/mL. The effect of P188 on normal plasma clotting parameters, such as PT and aPTT, was measured at a concentration range of 0-10 mg/mL. The effect of P188 on thrombin-induced clot formation was investigated using a fibrinokinetic method. The effect of P188 on thrombin generation was measured using the fluormetric method (Technoclone, Vienna, Austria). The anti-protease effects of P188 were studied using chromogenic substrate methods using isolated biochemical systems. Results At concentrations up to 10 mg/mL, P188 did not produce any modification of Celiteactivated clotting time (Celite-ACT).  At all concentrations the Celite-ACT values remained comparable to saline (138-140 sec for P188 vs. 140 sec for saline).  In the TEG analysis, P188 produced a concentrationdependent hypocoagulant effect in both native and citratedblood as evidenced by increased angle and shortening of maximum amplitude (MA).   In standard PT and aPTT tests, P188 did not produce any effect on the clotting profile at concentrations up to 20 mg/mL.  In fibrinokinetic studies, P188 produced an increase in the fibrin clot density and rate of fibrin polymerization. Discussion These studies demonstrate that even at very high concentrations, P188 does not produce an effect on whole blood clotting as measured by the Celite-ACT assay;   this result was confirmed in other standard assays.  Fibrinokinetic studies revealed an increase in the rate of fibrin formation and clot density.   However, at relatively low concentrations, P188 exhibited a hypocoagulant profile in TEG analysis.  The marked discordance between TEG and other coagulation tests suggest that P188’s effect on viscosity and adhesive interactions result in an artifact in TEG analysis and an incorrect indication of a hypocoagulant effect.  This effect may be due to the viscoelastic endpoint in the TEG assay. Further studies are needed to confirm this hypothesis. Disclosures: Fareed: Mast Therapeutics: Research Funding. Emanuele:Mast Therapeutics: Employment.


Sign in / Sign up

Export Citation Format

Share Document